StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Equities research analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 2.6 %

LPCN stock opened at $3.18 on Wednesday. The firm has a 50 day moving average of $3.23 and a 200-day moving average of $4.30. The firm has a market capitalization of $17.01 million, a P/E ratio of -4.18 and a beta of 1.51. Lipocine has a 12 month low of $2.75 and a 12 month high of $11.79.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.